The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
74
The First Hospital of Jilin University
Changchun, Jilin, China
Safety: incidence of adverse event (AE), serious adverse event (SAE)
Time frame: Day1-Day15 (SAD);Day1-Day15 (FE);Day1-Day21 (MAD)
PK parameter of HRS-8797 : Area under the concentration time curve (AUC)
Time frame: Days 1-19
PK parameter of HRS-8797: Maximum Plasma Concentration (Cmax)
Time frame: Days 1-19
PK parameter of HRS-8797 : Time to maximum plasma concentration (Tmax)
Time frame: Days 1-19
PK parameter of HRS-8797 : Apparent clearance (CL/F)
Time frame: Days 1-19
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.